I AM ALS announces grant from Poarch Band of Creek Indians
For immediate release
August 11, 2023, WASHINGTON, DC – I AM ALS recently received a $250,000 grant from the Poarch Band of Creek Indians. This generous gift was made in honor of Chad Klinck, Chief Financial Officer of Creek Indian Enterprises Development Authority, the economic development arm of the Poarch Band of Creek Indians. Chad was diagnosed with ALS in 2020.
“While I personally do not need anything, many people are not as lucky as myself. I’ve chosen a charity that helps patients with the disease and advocates nationally for patient funding and expanded access to medical trials,” Klinck said.
Founded in 2019, I AM ALS has facilitated significant strides for the community of people living with ALS in just five years, including quadrupling federal funding and galvanizing the community to successful FDA approval of three new ALS treatments.
Andrea Goodman, I AM ALS CEO, said, “This gift will enable us to continue our charge of empowering a community to make revolutionary policy, awareness, and treatment progress – ultimately leading to cures for ALS. We are incredibly grateful for this support and to Chad for his advocacy.”
About I AM ALS
I AM ALS is a patient-led community that provides support to those living with ALS, caregivers, and loved ones, and utilizes community action teams to empower advocates to raise awareness and lead the revolution against ALS in driving the development of cures.
About the Poarch Band of Creek Indian
The Poarch Band of Creek Indians is the only federally recognized tribe in Alabama. From hospitality to aerospace, we continue to operate in a variety of industries across the World. Read more about our Tribe here.
We will find cures for ALS. The only question is when. That answer depends on you.
Stay informed on I AM ALS’ progress and what you can do to help us make hope real.
I AM ALS responds to FDA Advisory Committee vote against NurOwn for the treatment of ALS
I AM ALS - an organization led for and by those living with and impacted by amyotrophic lateral sclerosis (ALS) - objects to today’s Cellular, Tissue, and Gene Therapies Advisory Committee (AdComm) vote of 17 to 1, with one member abstaining, to not recommend NurOwn be approved by the FDA for the treatment of ALS.
I AM ALS letter to FDA asking for consistency in Advisory Committee evaluation of ALS treatments
I AM ALS and members of the ALS community are disappointed that the question being posed to the Advisory Committee fails to adhere to the same pattern of flexibility recognizing the significant unmet medical need of ALS as was the case for previous Advisory Committee meetings for ALS treatments.